Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus

Lupus

Volumn 19, Issue 6, 2010, Pages 734-740

  Wang, J ^a   Nuite, M ^a   McAlindon, T E ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Aromatase; Case control; Estrogen receptor gene; Genetic polymorphism; Systemic lupus erythematosus

Indexed keywords

AROMATASE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ESTROGEN ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANIMALS; AROMATASE; CASE-CONTROL STUDIES; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERNET; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 77951232178     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309359517     Document Type: Article

References (47)

1. Masi AT, Kaslow RA Sex effects in systemic lupus erythematosus: a clue to pathogenesis. Arthritis Rheum 1978 ; 21: 480-484.
2. Ansar Ahmed S., Penhale WJ, Talal N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol 1985 ; 121: 531-551. (Pubitemid 16183373)
3. Cutolo M., Sulli A., Capellino S., et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 2004 ; 13: 635-638. (Pubitemid 39279773)
4. Carlsten H., Tarkowski A., Holmdahl R., Nilsson LA Oestrogen is a potent disease accelerator in SLE-prone MRL lpr/lpr mice. Clin Exp Immunol 1990 ; 80: 467-473. (Pubitemid 20180346)
5. Ahmed SA, Hissong BD, Verthelyi D., Donner K., Becker K., Karpuzoglu-Sahin E. Gender and risk of autoimmune diseases: possible role of estrogenic compounds. Environ Health Perspect 1999 ; 107 (Suppl. 5). 681-686. (Pubitemid 29527770)
6. Rider V., Jones S., Evans M., Bassiri H., Afsar Z., Abdou NI Estrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus. J Rheumatol 2001 ; 28: 2644-2649. (Pubitemid 33135648)
7. Kanda N., Tsuchida T., Tamaki K. Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1999 ; 42: 328-337. (Pubitemid 29072851)
8. Folomeev M., Dougados M., Beaune J., et al. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus 1992 ; 1: 191-195.
9. Weidler C., Harle P., Schedel J., Schmidt M., Scholmerich J., Straub RH Patients with rheumatoid arthritis and systemic lupus erythematosus have increased renal excretion of mitogenic estrogens in relation to endogenous antiestrogens. J Rheumatol 2004 ; 31: 489-494. (Pubitemid 38337606)
10. Sanchez-Guerrero J., Karlson EW, Liang MH, Hunter DJ, Speizer FE, Colditz GA Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997 ; 40: 804-808. (Pubitemid 27199994)
11. Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. Arthritis Rheum 2002 ; 46: 1830-1839. (Pubitemid 34774515)
12. Bengtsson AA, Rylander L., Hagmar L., Nived O., Sturfelt G. Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden. Rheumatology (Oxford) 2002 ; 41: 563-571. (Pubitemid 34567188)
13. Sanchez-Guerrero J., Liang MH, Karlson EW, Hunter DJ, Colditz GA Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995 ; 122: 430-433.
14. Meier CR, Sturkenboom MC, Cohen AS, Jick H. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J Rheumatol 1998 ; 25: 1515-1519. (Pubitemid 28364755)
15. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 2005 ; 142: 953-962.
16. Westberg L., Baghaei F., Rosmond R., et al. Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J Clin Endocrinol Metab 2001 ; 86: 2562-2568. (Pubitemid 32545707)
17. Sundarrajan C., Liao WX, Roy AC, Ng SC Association between estrogen receptor-beta gene polymorphisms and ovulatory dysfunctions in patients with menstrual disorders. J Clin Endocrinol Metab 2001 ; 86: 135-139. (Pubitemid 32109786)
18. Stavrou I., Zois C., Ioannidis JP, Tsatsoulis A. Association of polymorphisms of the oestrogen receptor alpha gene with the age of menarche. Hum Reprod 2002 ; 17: 1101-1105. (Pubitemid 34411153)
19. Salmen T., Heikkinen AM, Mahonen A., et al. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy. J Bone Miner Res 2000 ; 15: 315-321. (Pubitemid 30095719)
20. Ioannidis JP, Ralston SH, Bennett ST, et al. Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA 2004 ; 292: 2105-2114.
21. Shearman AM, Karasik D., Gruenthal KM, et al. Estrogen receptor beta polymorphisms are associated with bone mass in women and men: the Framingham Study. J Bone Miner Res 2004 ; 19: 773-781. (Pubitemid 41094389)
22. McAlindon T., Wang J., Formica M., et al. Feasibility and validity were demonstrated of an online case-control study using the prototype of recent-onset systemic lupus erythematosus. J Clin Epidemiol 2008 ; 61: 671-678.
23. Hochberg MC Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997 ; 40: 1725.
24. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982 ; 25: 1271-1277. (Pubitemid 13221242)
25. McAlindon TE, Formica M., Palmer JR, Lafyatis R., Rosenberg L. Assessment of strategies for identifying diagnosed cases of systemic lupus erythematosus through self-report. Lupus 2003 ; 12: 754-759. (Pubitemid 37295810)
26. Cooper GS, Gilkeson GS, Dooley MA, St. Clari EW, Treadwell EL, Pandey JP Medical history risk factors for the development of SLE: results from a population-based case-control study. American College of Rheumatology Annual Meeting, 1999.
27. Lum A., Le Marchand L. A simple mouthwash method for obtaining genomic DNA in molecular epidemiological studies. Cancer Epidemiol Biomarkers Prev 1998 ; 7: 719-724. (Pubitemid 28374603)
28. Yurino H., Ishikawa S., Sato T., et al. Endocrine disruptors (environmental estrogens) enhance autoantibody production by B1 Cells. Toxicol Sci 2004 ; 81: 139-147. (Pubitemid 39199872)
29. Costenbader KH, Feskanich D., Stampfer MJ, Karlson EW Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 2007 ; 56: 1251-1262. (Pubitemid 46608650)
30. Svenson JL, EuDaly J., Ruiz P., Korach KS, Gilkeson GS Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse. Clin Immunol 2008 ; 128: 259-268.
31. Bynote KK, Hackenberg JM, Korach KS, Lubahn DB, Lane PH, Gould KA Estrogen receptor-alpha deficiency attenuates autoimmune disease in (NZB x NZW)F1 mice. Genes Immun 2008 ; 9: 137-152.
32. Lee YJ, Shin KS, Kang SW, et al. Association of the oestrogen receptor alpha gene polymorphisms with disease onset in systemic lupus erythematosus. Ann Rheum Dis 2004 ; 63: 1244-1249. (Pubitemid 39273502)
33. Zhang QH, Cao J., Hu YZ, et al. Morphological observation of immunological alterations in the spleens from estrogen receptor deficient mice. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2004 ; 20: 1-6.
34. Eastwood H., Brown KM, Markovic D., Pieri LF Variation in the ESR1 and ESR2 genes and genetic susceptibility to anorexia nervosa. Mol Psychiatry 2002 ; 7: 86-89. (Pubitemid 34087884)
35. Scariano JK, Simplicio SG, Montoya GD, Garry PJ, Baumgartner RN Estrogen receptor beta dinucleotide (CA) repeat polymorphism is significantly associated with bone mineral density in postmenopausal women. Calcif Tissue Int 2004 ; 74: 501-508. (Pubitemid 38780285)
36. Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, MacDonald PC Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 1974 ; 38: 476-479.
37. Simpson ER, Zhao Y., Agarwal VR, et al. Aromatase expression in health and disease. Recent Prog Horm Res 1997 ; 52: 185-213 ; discussion 213-214. (Pubitemid 127470211)
38. Dick IM, Devine A., Prince RL Association of an aromatase TTTA repeat polymorphism with circulating estrogen, bone structure, and biochemistry in older women. Am J Physiol Endocrinol Metab 2005 ; 288: E989 - E995. (Pubitemid 40547894)
39. Gennari L., Masi L., Merlotti D., et al. A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab 2004 ; 89: 2803-2810. (Pubitemid 38766369)
40. Van Pottelbergh I., Goemaere S., Kaufman JM Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 2003 ; 88: 3075-3081. (Pubitemid 36877475)
41. Somner J., McLellan S., Cheung J., et al. Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2004 ; 89: 344-351. (Pubitemid 38183902)
42. Suzuki K., Nakazato H., Matsui H., et al. Association of the genetic polymorphism of the CYP19 intron 4[TTTA]n repeat with familial prostate cancer risk in a Japanese population. Anticancer Res 2003 ; 23: 4941-4946. (Pubitemid 38182108)
43. Baxter SW, Choong DY, Eccles DM, Campbell IG Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 2001 ; 22: 347-349. (Pubitemid 32175526)
44. Modugno F., Weissfeld JL, Trump DL, et al. Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 2001 ; 7: 3092-3096. (Pubitemid 32963829)
45. Liu ZH, Cheng ZH, Gong RJ, Liu H., Liu D., Li LS Sex differences in estrogen receptor gene polymorphism and its association with lupus nephritis in Chinese. Nephron 2002 ; 90: 174-180. (Pubitemid 34701993)
46. Johansson M., Arlestig L., Moller B., Smedby T., Rantapaa-Dahlqvist S. Oestrogen receptor {alpha} gene polymorphisms in systemic lupus erythematosus. Ann Rheum Dis 2005 ; 64: 1611-1617. (Pubitemid 41532046)
47. Sinha M., Larkin EK, Elston RC, Redline S. Self-reported race and genetic admixture. N Engl J Med 2006 ; 354: 421-422.